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Superantigens, Autoantigens, and Pathogenic T Cells in
Psoriasis
To the Editor:
In the past few years it has become clear that using human skin SCID
mouse xenografts as an experimental model of psoriasis provides new
opportunities for investigative skin biologists examining this common
and enigmatic disease (Nickoloff and Wrone-Smith, 1997). A recent
report employing this type of model, observed that T cells from lesional
(PP) skin were important in the maintenance of a psoriatic plaque
(Gilhar et al, 1997). Gilhar et al attribute this phenomenon to the
presence of autoreactive T cells, and contrast this approach that focused
on the maintenance of a lesion to other earlier reports, in which
lesions were actually created from symptomless (nonlesional; PN) skin
(Boehncke et al, 1996; Wrone-Smith and Nickoloff, 1996). In our
experience, during the past 2 y of research, we have found bacterial
derived superantigens to be potent inducers of blood derived T cell
activation that facilitates conversion of PN to PP skin after intradermal
injection. Gilhar et al suggest that, although the PN to PP model using
superantigens (‘‘superantigen model’’) is extremely useful, it may
not identify autoreactive T cells important in the pathophysiology
of psoriasis.
We disagree with this assessment. Indeed, we believe that both sets
of data concerning superantigens and autoantigens can be reconciled
into a coherent multistep model that has previously been put forward
for psoriasis (Nickoloff, 1991), as well as by scientists examining other
autoimmune diseases such as rheumatoid arthritis, diabetes mellitus
(Conrad et al, 1994), and multiple sclerosis (Brocke et al, 1993). Because
of clinical similarities between psoriasis and these autoimmune diseases,
important clues may be obtained by analyzing other well characterized
animal models examining the relationship between superantigen and
autoreactive T cells, as originally proposed by Marrack and Kappler
(1990). There are essentially two important steps postulated for
autoimmune pathways: first, superantigens induce a polyclonal activa-
tion of Vβ restricted T cell subsets that circulate throughout the
body, consisting of CD41 T cells activated by recognition of major
histocompatibility complex class II positive antigen presenting cells
bearing the superantigen (Leung et al, 1993). Second, a subset of
autoreactive T cells within this circulating pool of superantigen activated
T cells bearing the skin-homing receptor CLA (Leung et al, 1995)
would enter the skin, recognize an ‘‘autoantigen,’’ and initiate the
cascade of cellular and molecular events that produce psoriasis (primarily
keratinocyte hyperplasia, altered differentiation, and an angiogenic
tissue reaction). Upon the induction of massive keratinocyte activation
and hyperplasia, new antigens/epitopes will be generated with perpetu-
ation of T cell stimulation occurring via determinant spreading as
postulated for autoimmune diseases (Steinman, 1996; Tisch and
McDevitt, 1996). Interestingly, such autoimmune epitope spreading
(Reiser and Stadeiter, 1996) involves the same T cell costimulatory
molecules (CD28:CD80) that we have observed are important in the
activation of autoreactive T cells in the circulation of our patients with
psoriasis (Nestle et al, 1994).
The conceptual viewpoint emphasized in this text does not demand
one to choose between a superantigen versus an autoantigen as being
of exclusive relevance to the disease process. Rather it embraces the
notion that both types of T cells (i.e., superantigen activated T cells
as initiators of pathogenic events and autoreactive T cells as perpetuators
of the pathology necessary to maintain the lesion) are important
coconspirators in this immunologically mediated disease manifesting
itself in skin. Perhaps the most intriguing possibility amongst numerous
scenarios that one could imagine derives from a recent report in which
an endogenous retroviral derived superantigen is actually a candidate
autoimmune gene for type 1 diabetes (Conrad et al, 1997). In this
report they observed that Vβ restricted T cell proliferation was mediated
by monocytes transfected with sequences that encode for the retroviral
Figure 1. CD69 expression detected on lymphocytes near basal
epidermal keratinocytes in a psoriatic plaque (PP skin) converted from
symptomless (PN) skin. The human PN skin was grafted onto a SCID
mouse, and injected intradermally with an autologous CD41 T cell line as
described in the text. A biopsy of the skin lesion created was processed for frozen
section immunohistology using anti-CD69 monoclonal antibody (Becton-
Dickenson, Mountain View, CA), avidin-biotin staining (Vectastain Kit, Vector
Labs, Burlington, CA), with 3-amino-4-ethylcarbazole producing a positive
red reactive product. Scale bar, 10 µm.
derived superantigen. Not only are such results provocative in regard
to understanding the pathophysiology of psoriasis, but these same
results also have potentially significant implications for understanding
the genetics of psoriasis (Elder et al, 1994). For example, it is interesting
to note that the diabetes retrovirus related HLA-DQ-LTR has been
associated with disease susceptibility possibly related to cosegregation
with HLA (Badenhoop et al, 1996).
Evidence to support the notion that a population of T cells initially
stimulated by superantigens, and then subsequently re-activated by an
endogenous ‘‘auto-antigen,’’ is operative in psoriasis can be seen in
Fig 1. This biopsy was taken 2 wk after a CD41 T cell line was
injected into the dermis of PN skin as previously described (Wrone-
Smith and Nickoloff, 1996). Note the phenotypic conversion of
the skin with histologic evidence of psoriasis, accompanied by the
lymphocytic infiltrate in dermis and epidermis. Of particular relevance
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is the presence of CD69 positive T cells that are present at the dermal–
epidermal interface. We (Wrone-Smith and Nickoloff, unpublished
data), and others, have observed that CD69 is an acute T cell activation
antigen that is rapidly (4–6 h) induced by bacterial superantigen on
the surface of T cells after stimulation; but is down-modulated 6–8 d
later if no additional stimulus is provided (Caruso et al, 1997).
This CD41 T cell line was derived from peripheral blood mononu-
clear cells initially stimulated with bacterial superantigens SEB, SEC2,
and 20 U IL-2 per ml for 7 d; and then washed and followed by
negative selection using magnetic beads to yield highly purified (.98%)
CD41 T cells. These CD41 T cells were then maintained in culture
for several weeks using IL-2 alone. Next the CD41 T cells were
washed and injected into PN skin using phosphate-buffered saline
without any further exposure to superantigens or IL-2, with the PN
to PP conversion noted above developing 2 wk later. We suggest that
a reasonable explanation for this result is that T cells undergo a re-
stimulatory event once they contact the basal cell layer of keratinocytes
along the dermal–epidermal junction. This encounter results in renewed
T cell activation with induction of CD69 expression. This acute
activation event appears not to be a general phenomena as T cells in
the mid-dermis are CD69 negative. Studies are in progress to elucidate
the nature of this keratinocyte derived T cell activating agent, to
determine if it is an autoantigen or non-self derived peptide. We are
also currently attempting to determine if these CD691 lymphocytes
represent the injected blood derived T cells, or are autologous T cells
that were initially present in PN skin prior to engraftment, which
became secondarily activated after exposure to the injected T cells.
In conclusion, many new experimental approaches can be pursued
by the use of the SCID human skin xenograft based model for psoriasis.
Using this novel research tool it should be possible in the near future
to identify specific T cell clones that possess a pathogenic phenotype
(defined by converting PN to PP skin), and to elucidate its genotype,
nature of T cell receptor activating stimulus, and effector mechanism
by which these immunocompetent cells cause psoriatic skin lesions.
As we move forward the possibility that both exogenous factors (i.e.,
bacterial superantigens) and endogenous factors (major histocompat-
ibility complex class I/II haplotypes and autoantigens) play a comple-
mentary role in the T cell response should be considered by
investigators. Certainly, clinicians have long recognized that psoriasis
is likely to be multifactorial – being related to both environmental and
inherited triggering factors (Farber et al, 1987).
Brian J. Nickoloff, Tamara Wrone-Smith
Department of Pathology, Skin Cancer Research Laboratories,
Cardinal Bernardin Cancer Center,
Loyola University Medical Center, Maywood, Illinois
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